Stock Scorecard



Stock Summary for Lantheus Holdings Inc (LNTH) - $67.31 as of 1/12/2026 5:26:55 PM EST

Total Score

7 out of 30

Safety Score

43 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LNTH

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LNTH

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LNTH

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LNTH

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LNTH (43 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for LNTH

Technical Reactions to LNTH Trends in Macro Strategies 1/12/2026 7:26:00 PM
The Bull Case For Lantheus (LNTH) Could Change Following SPECT Exit And Neuro Imaging Refocus 1/9/2026 11:14:00 AM
The Bull Case For Lantheus (LNTH) Could Change Following SPECT Exit And Neuro Imaging Refocus 1/9/2026 5:38:00 AM
LNTH: Lantheus Closes SPECT Sale 1/8/2026 3:10:00 PM
LNTH Stock Price, Forecast & Analysis | LANTHEUS HOLDINGS INC (NASDAQ:LNTH) 1/7/2026 11:12:00 AM
ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics 1/6/2026 6:11:00 AM
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027 1/5/2026 4:08:00 PM
Stanley Laman Group Ltd. Acquires 22,229 Shares of Lantheus Holdings, Inc. $LNTH 1/5/2026 12:08:00 PM
A Look At Lantheus Holdings (LNTH) Valuation After Recent Short Term Share Price Momentum 1/5/2026 9:08:00 AM
Lantheus Closes SPECT Business Sale to SHINE Technologies 1/4/2026 6:09:00 AM

Financial Details for LNTH

Company Overview

Ticker LNTH
Company Name Lantheus Holdings Inc
Country N/A
Description Lantheus Holdings, Inc. is a prominent biotechnology company headquartered in North Billerica, Massachusetts, specializing in the development and commercialization of advanced diagnostic and therapeutic solutions, primarily targeting oncology and cardiology. Recognized for its innovative PET imaging agents, Lantheus is pivotal in enhancing the accuracy of cancer diagnosis and treatment management, thereby significantly improving patient outcomes. With a commitment to advancing healthcare through cutting-edge technology, Lantheus has solidified its position as a key player within the healthcare sector, driving innovation and improving patient care across its therapeutic focus areas.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - SPECIALTY & GENERIC
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 67.31
Price 4 Years Ago 50.96
Last Day Price Updated 1/12/2026 5:26:55 PM EST
Last Day Volume 904,171
Average Daily Volume 1,064,557
52-Week High 111.29
52-Week Low 47.25
Last Price to 52 Week Low 42.46%

Valuation Measures

Trailing PE N/A
Industry PE 114.75
Sector PE 123.98
5-Year Average PE 22.23
Free Cash Flow Ratio 11.69
Industry Free Cash Flow Ratio 12.83
Sector Free Cash Flow Ratio 29.04
Current Ratio Most Recent Quarter 2.67
Total Cash Per Share 5.76
Book Value Per Share Most Recent Quarter 16.88
Price to Book Ratio 4.09
Industry Price to Book Ratio 19.42
Sector Price to Book Ratio 24.69
Price to Sales Ratio Twelve Trailing Months 3.11
Industry Price to Sales Ratio Twelve Trailing Months 3.19
Sector Price to Sales Ratio Twelve Trailing Months 19.33
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 66,312,000
Market Capitalization 4,463,460,720
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -77.10%
Annual Earnings Growth -4.35%
Reported EPS 12 Trailing Months 2.41
Reported EPS Past Year 3.92
Reported EPS Prior Year 6.78
Net Income Twelve Trailing Months 167,681,000
Net Income Past Year 312,442,000
Net Income Prior Year 326,661,000
Quarterly Revenue Growth YOY 1.40%
5-Year Revenue Growth 34.59%
Operating Margin Twelve Trailing Months 11.40%

Balance Sheet

Total Cash Most Recent Quarter 382,006,000
Total Cash Past Year 912,814,000
Total Cash Prior Year 713,656,000
Net Cash Position Most Recent Quarter -185,931,000
Net Cash Position Past Year 347,535,000
Long Term Debt Past Year 565,279,000
Long Term Debt Prior Year 561,670,000
Total Debt Most Recent Quarter 567,937,000
Equity to Debt Ratio Past Year 0.66
Equity to Debt Ratio Most Recent Quarter 0.66
Total Stockholder Equity Past Year 1,088,011,000
Total Stockholder Equity Prior Year 815,892,000
Total Stockholder Equity Most Recent Quarter 1,119,206,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 406,279,000
Free Cash Flow Per Share Twelve Trailing Months 6.13
Free Cash Flow Past Year 493,125,000
Free Cash Flow Prior Year 258,705,000

Options

Put/Call Ratio 0.26
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.12
MACD Signal 2.35
20-Day Bollinger Lower Band 45.98
20-Day Bollinger Middle Band 58.45
20-Day Bollinger Upper Band 70.93
Beta -0.11
RSI 60.60
50-Day SMA 73.28
150-Day SMA 78.41
200-Day SMA 74.95

System

Modified 1/10/2026 2:47:05 AM EST